Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2019

View Archived Issues

Targeted protein degradation with DGY-08-097 shows promise for hepatitis C virus treatment

Discovery and preclinical characterization of c-KIT kinase inhibitor CHMFL-KIT-64

Vulnerable brains can be steered towards healthy development

Four-way interaction screen gives clues to drug effects

FDA clears IND application for phase I/II study of OBI-999

Inhibrx announces phase I dose-escalation data for INBRX-109

Kura Oncology presents phase II results for tipifarnib in HRAS-mutant urothelial carcinoma

Positive phase II data presented for CTP-543 in patients with alopecia areata

TAS-4464 demonstrates potent antitumor activity in hematologic and solid tumor models

BMS-986235 shows efficacy in preclinical models of heart failure

Fulacimstat does not improve standard of care treatment in CHIARA MIA 2 study

Biogen explores non-covalent activation of NRF2 for neurodegenerative and other disorders

Machine learning from adversity speeds compound development

Discovery of a first-in-class dual adenosine A2A/A2B receptor antagonist

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Pfizer synthesizes new KRAS inhibitors

Positive preclinical data presented for Cocrystal Pharma's CC-42344

Turning Point Therapeutics reports new data on repotrectinib and TPX-0046

Medshine Discovery divulges kynurenine production inhibitors

Phase II trial of AR-105 for ventilator-associated pneumonia does not meet primary endpoint

Jiangsu Aosaikang Pharmaceutical identifies H+/K+ ATPase inhibitors

Beijing Scitech-Mq Pharmaceuticals describes RET and VEGFR2 inhibitors

InnoCare Pharma identifies TRK inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...